|
|
|
|
||
MNKD Shorts Only Concentrate on Insurance Formulary Prescription Sales of AfrezzaThey don't mention: 1. The negotiating power of Pharmacy Benefit Managers re: Insurance Formularies 2. The poor commercial development of Afrezza under Sanofi 3. The lack of an organic MNKD Commercial Dept. until early 2016 4. The lack of an organic MNKD sales force until 2017 5. The lack of Afrezza tv commercials until late 2017 6. Trepostinil Technosphere and the future cash flow that it could bring 7. Other Technosphere molecules in development for future commercial development agreements. 8. That Technosphere development revenue is already higher than Afrezza revenue. 9. That hundreds of Afrezza users are making "life changing" comments about Afrezza on the Internet. JMHO. |
return to message board, top of board |
Msg # | Subject | Author | Recs | Date Posted |
16481 | Re: MNKD Shorts Only Concentrate on Formulary Sales of Afrezza | CTretired | 3 | 3/18/2019 1:56:34 PM |